UK prospective diabetes study (UKPDS) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1991-12

AUTHORS

UK Prospective Diabetes Study Group

ABSTRACT

The UK Prospective Diabetes Study (UKPDS) is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality. Newly presenting Type 2 diabetic patients aged 25–65 years inclusive, median age 53 years, median body mass index 28 kg/m2 and median fasting plasma glucose 11.3 mmol/l, were recruited and treated initially by diet. Ninety five percent remained hyperglycaemic (fasting plasma glucose > 6 mmol/l) and were randomly allocated to different therapies. In the main randomisation, those who were asymptomatic and had fasting plasma glucose under 15 mmol/l were allocated either to diet policy, or to active policy with either insulin or sulphonylurea aiming to reduce the fasting plasma glucose to under 6 mmol/l. Over 3 years, the median fasting plasma glucose in those allocated to diet policy was 8.9 mmol/l compared with 7.0 mmol/l in those allocated to active policy. The Hypertension in Diabetes Study has been included in a factorial design to assess whether improved blood pressure control will be advantageous. Patients with blood pressure ≥ 160/90 mm Hg were randomly allocated to tight control aiming for < 150/85 mm Hg with either an angiotensin-converting enzyme inhibitor or a Beta-blocker or to less tight control aiming for < 200/105 mm Hg. The endpoints of the studies are major clinical events which affect the life and well-being of patients, such as heart attacks, angina, strokes, amputations, blindness and renal failure. To date, 728 patients have had at least one clinical endpoint. Surrogate endpoints include indices of macrovascular and microvascular disease detected by ECG with Minnesota Coding, retinal colour photography and microalbuminuria. The studies also aim to evaluate potential risk factors for the development of diabetic complications such as smoking, obesity, central adiposity, plasma LDL-and HDL-cholesterol, triglyceride, insulin, urate and other biochemical variables. The studies are planned to terminate in 1994, with a median follow-up of 9 years (range 3–16 years) for the glucose study and 5 years (range 2–6 years) for the hypertension study. More... »

PAGES

877-890

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00400195

DOI

http://dx.doi.org/10.1007/bf00400195

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022043816

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1778353


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diet, Diabetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Royal Devon and Exeter Hospital, Exeter, UK", 
          "id": "http://www.grid.ac/institutes/grid.416118.b", 
          "name": [
            "Radcliffe Infirmary, Oxford", 
            "Royal Infirmary, Aberdeen", 
            "General Hospital, Birmingham", 
            "St George's Hospital and Hammersmith Hospital, London", 
            "City Hospital, Belfast", 
            "North Staffordshire Royal Infirmary, Stoke-on-Trent", 
            "Royal Victoria Hospital, Belfast", 
            "St. Helier Hospital, Carshalton", 
            "Whittington Hospital, London", 
            "Norfolk and Norwich Hospital, UK", 
            "Lister Hospital, Stevenage", 
            "Ipswich Hospital, UK", 
            "Ninewells Hospital, Dundee", 
            "Northampton Hospital, UK", 
            "Torbay Hospital, Peterborough General Hospital, UK", 
            "Scarborough Hospital, UK", 
            "Derbyshire Royal Infirmary, UK", 
            "Manchester Royal Infirmary, UK", 
            "Hope Hospital, Salford", 
            "Leicester General Hospital, UK", 
            "Royal Devon and Exeter Hospital, Exeter, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "UK Prospective Diabetes Study Group", 
        "id": "sg:person.014003710051.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014003710051.15"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00265546", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038663411", 
          "https://doi.org/10.1007/bf00265546"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00401052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044105011", 
          "https://doi.org/10.1007/bf00401052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00257424", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034044950", 
          "https://doi.org/10.1007/bf00257424"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00257337", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011564100", 
          "https://doi.org/10.1007/bf00257337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03216217", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025033216", 
          "https://doi.org/10.1007/bf03216217"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00282581", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032703668", 
          "https://doi.org/10.1007/bf00282581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00405009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048739310", 
          "https://doi.org/10.1007/bf00405009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00274216", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037368755", 
          "https://doi.org/10.1007/bf00274216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00297455", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008725966", 
          "https://doi.org/10.1007/bf00297455"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-12", 
    "datePublishedReg": "1991-12-01", 
    "description": "The UK Prospective Diabetes Study (UKPDS) is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality. Newly presenting Type 2 diabetic patients aged 25\u201365 years inclusive, median age 53 years, median body mass index 28 kg/m2 and median fasting plasma glucose 11.3 mmol/l, were recruited and treated initially by diet. Ninety five percent remained hyperglycaemic (fasting plasma glucose > 6 mmol/l) and were randomly allocated to different therapies. In the main randomisation, those who were asymptomatic and had fasting plasma glucose under 15 mmol/l were allocated either to diet policy, or to active policy with either insulin or sulphonylurea aiming to reduce the fasting plasma glucose to under 6 mmol/l. Over 3 years, the median fasting plasma glucose in those allocated to diet policy was 8.9 mmol/l compared with 7.0 mmol/l in those allocated to active policy. The Hypertension in Diabetes Study has been included in a factorial design to assess whether improved blood pressure control will be advantageous. Patients with blood pressure \u2265 160/90 mm Hg were randomly allocated to tight control aiming for < 150/85 mm Hg with either an angiotensin-converting enzyme inhibitor or a Beta-blocker or to less tight control aiming for < 200/105 mm Hg. The endpoints of the studies are major clinical events which affect the life and well-being of patients, such as heart attacks, angina, strokes, amputations, blindness and renal failure. To date, 728 patients have had at least one clinical endpoint. Surrogate endpoints include indices of macrovascular and microvascular disease detected by ECG with Minnesota Coding, retinal colour photography and microalbuminuria. The studies also aim to evaluate potential risk factors for the development of diabetic complications such as smoking, obesity, central adiposity, plasma LDL-and HDL-cholesterol, triglyceride, insulin, urate and other biochemical variables. The studies are planned to terminate in 1994, with a median follow-up of 9 years (range 3\u201316 years) for the glucose study and 5 years (range 2\u20136 years) for the hypertension study.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/bf00400195", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "34"
      }
    ], 
    "keywords": [
      "UK Prospective Diabetes Study", 
      "Prospective Diabetes Study", 
      "plasma glucose", 
      "Diabetes Study", 
      "angiotensin-converting enzyme inhibitor", 
      "improved blood glucose control", 
      "median age 53 years", 
      "type 2 diabetic patients", 
      "median body mass index", 
      "improved blood pressure control", 
      "type 2 diabetes mellitus", 
      "retinal colour photography", 
      "blood pressure control", 
      "age 53 years", 
      "major clinical events", 
      "HDL-cholesterol", 
      "body mass index", 
      "blood glucose control", 
      "potential risk factors", 
      "being of patients", 
      "associated morbidity", 
      "blood pressure", 
      "renal failure", 
      "microvascular disease", 
      "Glucose Study", 
      "diabetes mellitus", 
      "diabetic patients", 
      "mass index", 
      "central adiposity", 
      "glucose control", 
      "clinical events", 
      "Hypertension Study", 
      "intervention trials", 
      "clinical endpoints", 
      "risk factors", 
      "diabetic complications", 
      "Minnesota coding", 
      "different therapies", 
      "surrogate endpoints", 
      "plasma LDL", 
      "enzyme inhibitors", 
      "patients", 
      "pressure control", 
      "biochemical variables", 
      "heart attack", 
      "endpoints", 
      "complications", 
      "insulin", 
      "glucose", 
      "Hg", 
      "tight control", 
      "years", 
      "angina", 
      "color photography", 
      "microalbuminuria", 
      "hypertension", 
      "mellitus", 
      "morbidity", 
      "sulphonylureas", 
      "smoking", 
      "obesity", 
      "adiposity", 
      "study", 
      "control", 
      "randomisation", 
      "amputation", 
      "therapy", 
      "LDL", 
      "stroke", 
      "triglycerides", 
      "mortality", 
      "disease", 
      "trials", 
      "index", 
      "blindness", 
      "ECG", 
      "diet", 
      "inhibitors", 
      "percent", 
      "failure", 
      "factors", 
      "life", 
      "m2", 
      "events", 
      "date", 
      "pressure", 
      "factorial design", 
      "active policy", 
      "development", 
      "variables", 
      "being", 
      "attacks", 
      "photography", 
      "policy", 
      "design", 
      "coding", 
      "main randomisation"
    ], 
    "name": "UK prospective diabetes study (UKPDS)", 
    "pagination": "877-890", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022043816"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00400195"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1778353"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00400195", 
      "https://app.dimensions.ai/details/publication/pub.1022043816"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_258.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/bf00400195"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00400195'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00400195'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00400195'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00400195'


 

This table displays all metadata directly associated to this object as RDF triples.

262 TRIPLES      22 PREDICATES      145 URIs      127 LITERALS      18 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00400195 schema:about N03799bbf142d4f4db1aaecb84ec44414
2 N37a19dc96ff74f94b60c855c36c03071
3 N60ab1a48250f489993f24b486c3bf984
4 N6a5e45ece3a243469e04f1d218dac15e
5 N7a6f7b925a6946e09363cf73a72d3f5e
6 N819726b933ef41c5844d112c38540cd1
7 Nc60b9e36b81d471cb395bd4660b00166
8 Nc83747ba3de74a728ba7c0a98bf972ad
9 Nf3b58f45193f4a2ebe023b1ebce1871f
10 Nf7d39977e6aa4d3697caf471fb0e09ec
11 Nfb7b7a5e84a04ed2927550dd1f98675b
12 anzsrc-for:11
13 anzsrc-for:1102
14 anzsrc-for:1103
15 schema:author Nda2d5ebe77c44034afe0830fd783515a
16 schema:citation sg:pub.10.1007/bf00257337
17 sg:pub.10.1007/bf00257424
18 sg:pub.10.1007/bf00265546
19 sg:pub.10.1007/bf00274216
20 sg:pub.10.1007/bf00282581
21 sg:pub.10.1007/bf00297455
22 sg:pub.10.1007/bf00401052
23 sg:pub.10.1007/bf00405009
24 sg:pub.10.1007/bf03216217
25 schema:datePublished 1991-12
26 schema:datePublishedReg 1991-12-01
27 schema:description The UK Prospective Diabetes Study (UKPDS) is a multi-centre, prospective, randomised, intervention trial of 5100 newly-diagnosed patients with Type 2 (non-insulin-dependent) diabetes mellitus which aims to determine whether improved blood glucose control will prevent complications and reduce the associated morbidity and mortality. Newly presenting Type 2 diabetic patients aged 25–65 years inclusive, median age 53 years, median body mass index 28 kg/m2 and median fasting plasma glucose 11.3 mmol/l, were recruited and treated initially by diet. Ninety five percent remained hyperglycaemic (fasting plasma glucose > 6 mmol/l) and were randomly allocated to different therapies. In the main randomisation, those who were asymptomatic and had fasting plasma glucose under 15 mmol/l were allocated either to diet policy, or to active policy with either insulin or sulphonylurea aiming to reduce the fasting plasma glucose to under 6 mmol/l. Over 3 years, the median fasting plasma glucose in those allocated to diet policy was 8.9 mmol/l compared with 7.0 mmol/l in those allocated to active policy. The Hypertension in Diabetes Study has been included in a factorial design to assess whether improved blood pressure control will be advantageous. Patients with blood pressure ≥ 160/90 mm Hg were randomly allocated to tight control aiming for < 150/85 mm Hg with either an angiotensin-converting enzyme inhibitor or a Beta-blocker or to less tight control aiming for < 200/105 mm Hg. The endpoints of the studies are major clinical events which affect the life and well-being of patients, such as heart attacks, angina, strokes, amputations, blindness and renal failure. To date, 728 patients have had at least one clinical endpoint. Surrogate endpoints include indices of macrovascular and microvascular disease detected by ECG with Minnesota Coding, retinal colour photography and microalbuminuria. The studies also aim to evaluate potential risk factors for the development of diabetic complications such as smoking, obesity, central adiposity, plasma LDL-and HDL-cholesterol, triglyceride, insulin, urate and other biochemical variables. The studies are planned to terminate in 1994, with a median follow-up of 9 years (range 3–16 years) for the glucose study and 5 years (range 2–6 years) for the hypertension study.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree true
31 schema:isPartOf N55da0ea1b1bf4a4eb62b71bd12de6eab
32 Nae90e4c13c834f3f9f5b0da8f8a7a2e5
33 sg:journal.1001482
34 schema:keywords Diabetes Study
35 ECG
36 Glucose Study
37 HDL-cholesterol
38 Hg
39 Hypertension Study
40 LDL
41 Minnesota coding
42 Prospective Diabetes Study
43 UK Prospective Diabetes Study
44 active policy
45 adiposity
46 age 53 years
47 amputation
48 angina
49 angiotensin-converting enzyme inhibitor
50 associated morbidity
51 attacks
52 being
53 being of patients
54 biochemical variables
55 blindness
56 blood glucose control
57 blood pressure
58 blood pressure control
59 body mass index
60 central adiposity
61 clinical endpoints
62 clinical events
63 coding
64 color photography
65 complications
66 control
67 date
68 design
69 development
70 diabetes mellitus
71 diabetic complications
72 diabetic patients
73 diet
74 different therapies
75 disease
76 endpoints
77 enzyme inhibitors
78 events
79 factorial design
80 factors
81 failure
82 glucose
83 glucose control
84 heart attack
85 hypertension
86 improved blood glucose control
87 improved blood pressure control
88 index
89 inhibitors
90 insulin
91 intervention trials
92 life
93 m2
94 main randomisation
95 major clinical events
96 mass index
97 median age 53 years
98 median body mass index
99 mellitus
100 microalbuminuria
101 microvascular disease
102 morbidity
103 mortality
104 obesity
105 patients
106 percent
107 photography
108 plasma LDL
109 plasma glucose
110 policy
111 potential risk factors
112 pressure
113 pressure control
114 randomisation
115 renal failure
116 retinal colour photography
117 risk factors
118 smoking
119 stroke
120 study
121 sulphonylureas
122 surrogate endpoints
123 therapy
124 tight control
125 trials
126 triglycerides
127 type 2 diabetes mellitus
128 type 2 diabetic patients
129 variables
130 years
131 schema:name UK prospective diabetes study (UKPDS)
132 schema:pagination 877-890
133 schema:productId Na423ce8618a54276b56a9e905ecca3e1
134 Nb03d1586858649c88486d64d3671d480
135 Nc6715393c67e49fda9effc21606be273
136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022043816
137 https://doi.org/10.1007/bf00400195
138 schema:sdDatePublished 2021-11-01T18:00
139 schema:sdLicense https://scigraph.springernature.com/explorer/license/
140 schema:sdPublisher Nd329ade4db234bb987e811c6f08b5c77
141 schema:url https://doi.org/10.1007/bf00400195
142 sgo:license sg:explorer/license/
143 sgo:sdDataset articles
144 rdf:type schema:ScholarlyArticle
145 N03799bbf142d4f4db1aaecb84ec44414 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Research Design
147 rdf:type schema:DefinedTerm
148 N37a19dc96ff74f94b60c855c36c03071 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Humans
150 rdf:type schema:DefinedTerm
151 N55da0ea1b1bf4a4eb62b71bd12de6eab schema:issueNumber 12
152 rdf:type schema:PublicationIssue
153 N60ab1a48250f489993f24b486c3bf984 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Diabetes Mellitus, Type 2
155 rdf:type schema:DefinedTerm
156 N6a5e45ece3a243469e04f1d218dac15e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Antihypertensive Agents
158 rdf:type schema:DefinedTerm
159 N7a6f7b925a6946e09363cf73a72d3f5e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Prospective Studies
161 rdf:type schema:DefinedTerm
162 N819726b933ef41c5844d112c38540cd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name United Kingdom
164 rdf:type schema:DefinedTerm
165 Na423ce8618a54276b56a9e905ecca3e1 schema:name pubmed_id
166 schema:value 1778353
167 rdf:type schema:PropertyValue
168 Nae90e4c13c834f3f9f5b0da8f8a7a2e5 schema:volumeNumber 34
169 rdf:type schema:PublicationVolume
170 Nb03d1586858649c88486d64d3671d480 schema:name dimensions_id
171 schema:value pub.1022043816
172 rdf:type schema:PropertyValue
173 Nc60b9e36b81d471cb395bd4660b00166 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Adult
175 rdf:type schema:DefinedTerm
176 Nc6715393c67e49fda9effc21606be273 schema:name doi
177 schema:value 10.1007/bf00400195
178 rdf:type schema:PropertyValue
179 Nc83747ba3de74a728ba7c0a98bf972ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Middle Aged
181 rdf:type schema:DefinedTerm
182 Nd329ade4db234bb987e811c6f08b5c77 schema:name Springer Nature - SN SciGraph project
183 rdf:type schema:Organization
184 Nda2d5ebe77c44034afe0830fd783515a rdf:first sg:person.014003710051.15
185 rdf:rest rdf:nil
186 Nf3b58f45193f4a2ebe023b1ebce1871f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Hypertension
188 rdf:type schema:DefinedTerm
189 Nf7d39977e6aa4d3697caf471fb0e09ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Diet, Diabetic
191 rdf:type schema:DefinedTerm
192 Nfb7b7a5e84a04ed2927550dd1f98675b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Blood Glucose
194 rdf:type schema:DefinedTerm
195 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
196 schema:name Medical and Health Sciences
197 rdf:type schema:DefinedTerm
198 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
199 schema:name Cardiorespiratory Medicine and Haematology
200 rdf:type schema:DefinedTerm
201 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
202 schema:name Clinical Sciences
203 rdf:type schema:DefinedTerm
204 sg:journal.1001482 schema:issn 0012-186X
205 1432-0428
206 schema:name Diabetologia
207 schema:publisher Springer Nature
208 rdf:type schema:Periodical
209 sg:person.014003710051.15 schema:affiliation grid-institutes:grid.416118.b
210 schema:familyName UK Prospective Diabetes Study Group
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014003710051.15
212 rdf:type schema:Person
213 sg:pub.10.1007/bf00257337 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011564100
214 https://doi.org/10.1007/bf00257337
215 rdf:type schema:CreativeWork
216 sg:pub.10.1007/bf00257424 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034044950
217 https://doi.org/10.1007/bf00257424
218 rdf:type schema:CreativeWork
219 sg:pub.10.1007/bf00265546 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038663411
220 https://doi.org/10.1007/bf00265546
221 rdf:type schema:CreativeWork
222 sg:pub.10.1007/bf00274216 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037368755
223 https://doi.org/10.1007/bf00274216
224 rdf:type schema:CreativeWork
225 sg:pub.10.1007/bf00282581 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032703668
226 https://doi.org/10.1007/bf00282581
227 rdf:type schema:CreativeWork
228 sg:pub.10.1007/bf00297455 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008725966
229 https://doi.org/10.1007/bf00297455
230 rdf:type schema:CreativeWork
231 sg:pub.10.1007/bf00401052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044105011
232 https://doi.org/10.1007/bf00401052
233 rdf:type schema:CreativeWork
234 sg:pub.10.1007/bf00405009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048739310
235 https://doi.org/10.1007/bf00405009
236 rdf:type schema:CreativeWork
237 sg:pub.10.1007/bf03216217 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025033216
238 https://doi.org/10.1007/bf03216217
239 rdf:type schema:CreativeWork
240 grid-institutes:grid.416118.b schema:alternateName Royal Devon and Exeter Hospital, Exeter, UK
241 schema:name City Hospital, Belfast
242 Derbyshire Royal Infirmary, UK
243 General Hospital, Birmingham
244 Hope Hospital, Salford
245 Ipswich Hospital, UK
246 Leicester General Hospital, UK
247 Lister Hospital, Stevenage
248 Manchester Royal Infirmary, UK
249 Ninewells Hospital, Dundee
250 Norfolk and Norwich Hospital, UK
251 North Staffordshire Royal Infirmary, Stoke-on-Trent
252 Northampton Hospital, UK
253 Radcliffe Infirmary, Oxford
254 Royal Devon and Exeter Hospital, Exeter, UK
255 Royal Infirmary, Aberdeen
256 Royal Victoria Hospital, Belfast
257 Scarborough Hospital, UK
258 St George's Hospital and Hammersmith Hospital, London
259 St. Helier Hospital, Carshalton
260 Torbay Hospital, Peterborough General Hospital, UK
261 Whittington Hospital, London
262 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...